RT @ldlynd: The future of rare disease therapy. The number of potential new treatments is a good thing, but our ability to fund new treatme…
New Pub from CORE's Larry Lynd: When zebras run with horses–inherited metabolic diseases come mainstream. Reviews in Endocrine and Metabolic Disorders https://t.co/ExSVMoH3s1 @ldlynd
RT @ldlynd: The future of rare disease therapy. The number of potential new treatments is a good thing, but our ability to fund new treatme…
RT @ldlynd: The future of rare disease therapy. The number of potential new treatments is a good thing, but our ability to fund new treatme…
RT @ldlynd: The future of rare disease therapy. The number of potential new treatments is a good thing, but our ability to fund new treatme…
The future of rare disease therapy. The number of potential new treatments is a good thing, but our ability to fund new treatments, and the need for more specialists trained in patient care is a concern. https://t.co/P8GcsHACYe